Palade Codrina-Madalina, Vulpoi Georgiana-Anca, Vulpoi Radu-Alexandru, Drug Vasile Liviu, Barboi Oana-Bogdana, Ciocoiu Manuela
"Socola" Institute of Psychiatry, 700282 Iasi, Romania.
Neurology Department I, "Prof. Dr. N. Oblu" Emergency Clinical Hospital, 700309 Iasi, Romania.
Life (Basel). 2022 Aug 19;12(8):1263. doi: 10.3390/life12081263.
Globally, metabolic diseases such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease pose a major public health threat. Many studies have confirmed the causal relationship between risk factors and the etiopathogenesis of these diseases. Despite this, traditional therapeutic management methods such as physical education and diet have proven insufficient. Recently, researchers have focused on other potential pathways for explaining the pathophysiological variability of metabolic diseases, such as the involvement of the intestinal microbiota. An understanding of the relationship between the microbiome and metabolic diseases is a first step towards developing future therapeutic strategies. Currently, much attention is given to the use of biotics family members such as prebiotics (lactolose, soy oligosaccharides, galactooligosaccharides, xylooligosaccharides or inulin) and probiotics (genera Lactobacillus, Bifidobacterium, Lactococcus, Streptococcus or Enterococcus). They can be used both separately and together as synbiotics. Due to their direct influence on the composition of the intestinal microbiota, they have shown favorable results in the evolution of metabolic diseases. The expansion of the research area in the biotics family has led to the discovery of new members, like postbiotics. In the age of personalized medicine, their use as therapeutic options is of great interest to our study.
在全球范围内，肥胖、2型糖尿病和非酒精性脂肪性肝病等代谢性疾病对公众健康构成了重大威胁。许多研究已经证实了风险因素与这些疾病的病因发病机制之间的因果关系。尽管如此，诸如体育锻炼和饮食等传统治疗管理方法已被证明并不充分。最近，研究人员将重点放在了解释代谢性疾病病理生理变异性的其他潜在途径上，比如肠道微生物群的参与。了解微生物组与代谢性疾病之间的关系是制定未来治疗策略的第一步。目前，人们非常关注益生元（乳糖、大豆低聚糖、低聚半乳糖、低聚木糖或菊粉）和益生菌（乳酸杆菌属、双歧杆菌属、乳球菌属、链球菌属或肠球菌属）等生物制剂家族成员的使用。它们既可以单独使用，也可以作为合生元一起使用。由于它们对肠道微生物群组成有直接影响，在代谢性疾病的发展过程中已显示出良好效果。生物制剂家族研究领域的扩展导致了新成员的发现，如后生元。在个性化医疗时代，它们作为治疗选择的用途是我们研究的一大兴趣点。
